The FTC called out the nation’s leading pharmacy benefit managers for inflating pharmacy costs, affecting both employers and ...

Pharmacy benefit managers overcharged for specialty generic medications — in many cases by hundreds and thousands of percent ...

At a public meeting held on January 15, 2025, the Federal Trade Commission (FTC) summarized the Second Interim Staff Report ...

A yearslong Federal Trade Commission probe, resulting in a report released in July, reported that of the six pharmacy benefit ...

The Iowa legislation would require PBMs to reimburse pharmacies for the national or Iowa average acquisition drug costs.

The report shows that PBMs made over $7.3 billion in extra profits from dispensing specialty generic drugs during the study ...

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus. Lantus cost $292 for a 30-day supply. Drugmaker Viatris launched two versions ...

Pharmacy benefit managers are the middlemen in the prescription drug market. The Federal Trade Commission reports the revenue of four PBMs exceeds $1 trillion and they control 86% of the market.

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.

When talking about the influence of pharmacy benefit managers, U.S. Sen. James Lankford exhibits a mastery of how companies like CVS Health control where patients get their medicine, what ...